Hikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average – Here’s Why

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of GBX 1,495.66 and traded as high as GBX 1,632. Hikma Pharmaceuticals shares last traded at GBX 1,620, with a volume of 524,176 shares trading hands.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Citigroup lifted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Berenberg Bank increased their target price on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a report on Tuesday, August 11th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a research report on Friday, September 25th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average price target of GBX 2,085.83.

Hikma Pharmaceuticals Trading Down 2.4%

The stock has a market cap of £3.33 billion, a price-to-earnings ratio of 9.13, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The company’s 50 day simple moving average is GBX 1,607.21 and its two-hundred day simple moving average is GBX 1,498.52.

Insider Activity at Hikma Pharmaceuticals

In related news, insider Tobias Hestler purchased 7,500 shares of the stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by corporate insiders.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.